Yes I know they are eligible, it's not a question of eligibility. If dimerix get to week 36 data which isn't suffiently robust they won't get to sell the drug till after week 108. Retrophin were eligible till the FDA saw the quality of the data.
what I'm saying is a 108 week study in 300 patients doesn't seem viable for 20m
Ann: Dimerix Confirms Phase 3 FSGS Study Design With EMA, page-20
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.0¢ |
Change
0.040(8.89%) |
Mkt cap ! $269.6M | |||
| Open | High | Low | Value | Volume |
| 46.0¢ | 50.5¢ | 46.0¢ | $2.255M | 4.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.5¢ | 21052 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |